



REVIEW







iii 01 - 03 MARCH, 2024



BALI NUSA DUA CONVENTION CENTER, BALI, INDONESIA

BEST OF SAN ANTONIO BREAST CANCER SYMPOSIUM





01 March, 2024 (Friday) 💛 14:00 – 16:40 Hrs Bali, Indonesia Time



14:00 - 14:30

Screening and Surgical Oncology

Speaker: PETER DUBSKY, SWITZERLAND

- GS03-02: Mammographic surveillance in early breast cancer patients aged 50 years or over: results of the Mammo-50 non-inferiority trial of annual versus less frequent mammography
- GS02-02: Are nodal ITCs after neoadjuvant chemotherapy an indication for axillary dissection? The OPBC05/EUBREAST-14R/ICARO study
- GS02-06: Recurrence-free survival following sentinel node-positive breast cancer without completion axillary lymph node dissection - first results from the international randomized SENOMAC trial
- GS02-04: Surgical Treatment of Women with Breast Cancer and a BRCA1 Mutation: An International Analysis of the Impact of Bilateral Mastectomy on Survival

14:30 - 15:00

Radiation Oncology

Speaker: FAYE LIM, SINGAPORE

- GS02-07: Loco-Regional Irradiation in Patients with Biopsy-proven Axillary Node Involvement at Presentation Who Become Pathologically Node-negative After Neoadjuvant Chemotherapy: Primary Outcomes of NRG Oncology/NSABP B-51/RTOG 1304
- GS02-08: Five-year outcomes of the IDEA trial of endocrine therapy without radiotherapy after breast-conserving surgery for postmenopausal patients age 50-69 with genomically-selected favourable Stage I breast cancer
- GS03-01: Magnetic Resonance Imaging and a 12-Gene Expression Assay to Optimize Local Therapy for Ductal Carcinoma In Situ: 5-year clinical outcomes of E4112

15:00 - 15:30

Early-Stage Hormone Receptor Positive Breast Cancer

Speaker: JAVIER CORTES, SPAIN

- GS1-01: Biomarker results in high-risk estrogen receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer following neoadjuvant chemotherapy ±nivolumab: an exploratory analysis of CheckMate7FL
- GS01-02: Phase 3 study of neoadjuvant pembrolizumab or placebo plus

apbcs.org













iii 01 - 03 MARCH, 2024



BALI NUSA DUA CONVENTION CENTER, BALI, INDONESIA

BEST OF SAN ANTONIO BREAST CANCER SYMPOSIUM





01 March, 2024 (Friday) (14:00 - 16:40 Hrs Bali, Indonesia Time



chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2- breast cancer: KEYNOTE-756

- GS03-03: Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2- early breast cancer: final invasive disease-free survival (iDFS) analysis from the NATALEE trial
- GS03-06: Genomic and transcriptomic profiling of primary tumors from patients with HR+, HER2-, node-positive, high-risk early breast cancer in the monarchE trial

15:30 - 16:00

Early stage Triple Negative Breast Cancer/HER2 positive Breast Cancer/Survivorship Speaker: TIRA TAN, SINGAPORE

- GS01-03: Adding atezolizumab to adjuvant chemotherapy for stage II and III triplenegative breast cancer is unlikely to improve efficacy: interim analysis of the ALEXANDRA/IMpassion030 phase 3 trial
- GS03-12: Phase III study of adjuvant ado-trastuzumab emtansine vs trastuzumab for residual invasive HER2-positive early breast cancer after neoadjuvant chemotherapy and HER2-targeted therapy: KATHERINE final IDFS and updated OS analysis
- GS02-11: Fertility preservation and assisted reproductive technologies (ART) in breast cancer (BC) patients (pts) interrupting endocrine therapy (ET) to attempt pregnancy
- GS02-13: Pregnancy after breast cancer in young women with germline BRCA pathogenic variants: results from an international cohort study

16:00 - 16:20

Advanced Triple Negative and HER2 positive negative Breast Cancer Speaker: HOPE RUGO, USA

- GS01-05: Pembrolizumab + Olaparib vs Pembrolizumab + Chemotherapy After Induction With Pembrolizumab + Chemotherapy for Locally Recurrent Inoperable or Metastatic TNBC: Randomized Open-Label Phase 2 KEYLYNK-009 Study
- GS01-10: HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-Positive Metastatic Breast Cancer


apbcs.org





REVIEW





BALI NUSA DUA CONVENTION CENTER, BALI, INDONESIA

BEST OF SAN ANTONIO BREAST CANCER SYMPOSIUM





01 March, 2024 (Friday) (14:00 - 16:40 Hrs Bali, Indonesia Time

ABCS



16:20 - 16:40 |

Advanced ER Positive HER2 Negative Breast Cancer

Speaker: LEE SOO CHIN, SINGAPORE

- GS02-01: Randomized phase 3 study of datopotamab deruxtecan vs chemotherapy for patients with previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer: Results from TROPION-Breast01
- GS03-13: Phase III study of inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutant, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: INAVO120 primary analysis
- GS01-12: MONARCH 3: Final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+, HER2- advanced breast cancer